Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The following Medical Sciences Division’s professors were elected as Fellows of the Academy of Medical Sciences today:

  • Professor Matthew Freeman FRS, Professor of Pathology and Head of Dunn School of Pathology
  • Professor Simon Hay, Professor of Epidemiology, Wellcome Trust Centre for Human Genetics, Nuffield Department of Clinical Medicine
  • Professor Ian Pavord, Professor of Respiratory Medicine, Nuffield Department of Clinical Medicine
  • Professor Irene Tracey, Nuffield Professor Anasthetic Science and Head Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neurosciences

They join over a 1000 distinguished scientists, recognised by the Academy for their outstanding contributions and continued excellence in medical sciences.

Professor Alastair Buchan, Dean of Medicine and Head of Division commented: “I should like to take this opportunity to congratulate Matthew, Simon, Ian and Irene. They are truly worthy of this prestigious honour, working tirelessly as they do, in their respective areas to further our collective knowledge. We have such a dedicated and exceptional group of staff in the Medical Sciences Division, and the achievement of these four only further highlights our strengths across the medical sciences.”

Links:

Read more (Academy of Medical Sciences website) 

Related news (Nuffield Department of Clinical Medicine website)

Related news (Nuffield Department of Clinical Neurosciences website)

 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.